

AI4PHARMA TECH LIMITED

AI4PHARMA TECH LIMITED

CIN: U63999GJ2024PLC155084

REGISTERED OFFICE: D 510 THE FIRST BS KESHAV, BAUG PARTY PLOT, I I M, AHMEDABAD,
GUJARAT, INDIA, 380015

Sr. No.	Name	Designation
1.	Mr. Minesh Vinodchandra Doshi	Director
2.	Mr. Amish Vyas Pravinchandra	Director
3.	Mr. Akshat Minesh Doshi	Director

Notice

To,

The Members of M/s. AI4Pharma Tech Limited

NOTICE is hereby given that the 2nd (Second) Annual General Meeting of the Members of AI4Pharma Tech Limited will be held on 24th August 2026, at 02:00 P.M. at its registered office to transact the following business.

ORDINARY BUSINESS:

1. To consider and adopt the audited financial statements of the Company for the financial year ended March 31, 2026 and the reports of the Board of Directors ("the Board") and auditors thereon.
2. To appoint Director in place of Mr. Akshat Minesh Doshi (DIN: 10774141), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.

To consider and, if thought fit, to pass the following Resolution as an **Ordinary Resolution:**



AI4PHARMA TECH LIMITED

"RESOLVED THAT Mr. Akshat Minesh Doshi (DIN: 10774141), who retires by rotation and being eligible for re-appointment, be and is hereby re-appointed as a Director of the Company."

Regd. Office:
D 510 The First BS Keshav baug
Party Plot, I I M, Ahmedabad,
Gujarat, India, 380015

By order of the Board
AI4Pharma Tech Limited



Akshat
Mr. Akshat Doshi
(Director)
(DIN: 10774141)

AI4PHARMA TECH LIMITED

BOARDS' REPORT

To,

The Members,

AI4PHARMA TECH LIMITED,

D 510 The First BS Keshav baug Party Plot,

I I M, Ahmedabad, Gujarat, India, 380015

Your directors are pleased to present the 2nd Directors Report on the business and operations of the Company, along with the Audited Financial Statements and the Auditors' Report of your Company for the financial year ended, 31st March, 2026.

1. FINANCIAL PERFORMANCE OF THE COMPANY:

The Board's Report has been prepared based on the Financial Statements of the Company. The Financial results for the financial year are as below:

Particulars	2025-26	2024-25
Revenue from Operations	08.87	00.00
Other Income	00.00	00.00
Total Revenue	08.87	00.00
Less: Expenses before Interest and Depreciation	06.13	(00.25)
Less: (a) Finance Costs	0.38	00.00
(b) Depreciation	2.75	00.00
Profit / (Loss) before exceptional and extraordinary items and tax	(00.39)	(00.25)
Add: Exceptional Item	-	-
Profit/ (Loss) before tax	(00.39)	(00.25)

D 510 The First BS Keshav baug Party Plot, IIM, Ahmedabad, Ahmadabad City, Gujarat, India, 380015
CIN: U63999GJ2024PLC155084 Email Id: info@ai4pharmatech.com Phone: +91 9909200002



AI4PHARMA TECH LIMITED

Less: Tax Expenses	-	-
Current Tax	-	-
Tax of Earlier Year	-	-
Deferred Tax	01.13	-
Profit / (Loss) for the year	(01.52)	(00.25)

2. TRANSFER TO RESERVES

The Board of Directors of the Company does not propose to transfer any amount to the General Reserve of the Company.

3. DIVIDEND

Your directors do not recommend dividend to the shareholders of the Company for the Financial Year 2025-26.

4. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND

The provisions relating to transfer of unclaimed dividend to the Investor Education and Protection Fund under Section 125 of the Companies Act, 2013 are not applicable to the Company."

5. STATE OF COMPANY'S AFFAIRS:

The Company, in its financial year ended 31st March 2026, reported no operating revenue. The net loss for the year stood at Rs. 1.52 Lakhs.

6. CHANGE IN THE NATURE OF BUSINESS

During the Financial Year 2025-26, there was no change in the nature of the business of the Company.

7. CHANGE IN THE REGISTERED OFFICE OF THE COMPANY

There was no change in the registered office of the company during the financial year 2025-2026.



AI4PHARMA TECH LIMITED

8. SECRETARIAL STANDARDS

The Company has complied with Secretarial Standards issued by the Institute of Company Secretaries of India as applicable on meetings of the Board of Directors and General meetings.

9. DIRECTORS' RESPONSIBILITY STATEMENT

In accordance with the provisions of Section 134 (5) of the Companies Act, 2013, the Board hereby submits its Responsibility Statement: -

- I. In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures; if any
- II. The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the Loss of the company for that period;
- III. The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- IV. The directors had prepared the annual accounts on a going concern basis;
- V. The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

10. PUBLIC DEPOSITS

The Company has neither accepted nor renewed any deposits falling within the purview of Section 73 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014 as amended from time to time, during the year under review and therefore details mentioned in Rule 8(5) (v) & (vi) of Companies (Accounts) Rules, 2014 relating to deposits, covered under Chapter V of the Act is not required to be given.



AI4PHARMA TECH LIMITED

11. MONEY RECEIVED FORM DIRECTOR & THEIR RELATIVES

During the financial year, the Company has received a sum of ₹ 18,31,986 from Mr. Amish Vyas, Director of the Company. The amount received qualifies as exempt under Clause (viii) of Rule 2 of the Companies (Acceptance of Deposits) Rules, 2014, being monies received from a director out of his own funds.

As on 31st March 2026, the outstanding balance of monies received from Directors and their relatives is ₹ 20,69,395.

12. CAPITAL STRUCTURE

There was no change in the capital structure of the company during the year under review. The authorized share capital of the company is Rs. 10,00,000/- divided into 1,00,000 equity shares of Rs. 10/- each and the paid-up share of the company is Rs. 10,00,000/- divided into 1,00,000 equity shares of Rs. 10/- each.

13. DIRECTORS AND KEY MANAGERIAL PERSONNEL

A) Composition:

Your Company had three directors on its Board as of 31st March, 2026 and the Board is properly constituted. There was no appointment of additional directors, alternate directors and directors to fill the casual vacancy during the Financial Year under review.

Sr. No	Name of Directors & KMP	Designation	Date of Appointment	Date of Cessation
1.	MINESH VINODCHANDRA DOSHI	Director	10/09/2024	-
2.	AMISH VYAS PRAVINCHANDRA	Director	10/09/2024	-
3.	AKSHAT MINESH DOSHI	Director	10/09/2024	-

B) Induction, Re-Appointment and Resignation:



AI4PHARMA TECH LIMITED

During the Year under review, there were no changes in the composition of the Board of Directors of the Company.

C) Declaration by an Independent Director(s) and re- appointment, if any:

The provisions of section 149 of the Companies Act, 2013 pertaining to the appointment of Independent Directors do not apply to the Company.

D) Formal Annual Evaluation

AI4PHARMA TECH LIMITED, Unlisted Public Company is not covered under the applicability thresholds prescribed under Section 134(3) (p) of the Companies Act, 2013 and Rule 8(4) of the Companies (Accounts) Rules, 2014. Accordingly, the requirement to conduct a formal annual evaluation of the performance of the Board, its committees, and individual Directors does not apply to the Company for the financial year ended 31st March 2026.

14. NUMBER OF MEETINGS OF THE BOARD

The Board met 4 (Four) times during the year on the Following dates tabled below. The intervening gap between the meetings was within the period as prescribed under the Companies Act, 2013.

Sr. No.	Date of Board Meetings	Attendance		
		Mr. Minesh Vinodchandra Doshi	Mr. Amish Vyas PravinChandra	Mr. Akshat Minesh Doshi
1	08.05.2025	Present	Present	Present
2	14.08.2025	Present	Present	Present
3	24.10.2025	Present	Present	Present
4	10.02.2026	Present	Present	Present

15. COMMITTEES OF THE BOARD OF DIRECTORS OF THE COMPANY

There is no committee constituted in the company as the same is not applicable.

16. GENERAL BODY MEETINGS



AI4PHARMA TECH LIMITED

The first Annual General Meeting (AGM) of the Company was held on August 26, 2025, in accordance with the provisions of Section 96 of the Companies Act, 2013. The Members considered and approved the Audited Financial Statements of the Company for the financial year ended March 31, 2025, together with the Reports of the Board of Directors and the Auditors thereon.

- **EXTRA-ORDINARY GENERAL MEETING (EOGM):**

There was no Extra Ordinary General Meeting held during the year under consideration.

17. ANNUAL RETURN:

As per the provisions of Section 92(3) and Section 134(3) (a) of the Act, the Company is required to upload a copy of the annual return on its website, if any, and the web-link of such annual return shall be disclosed in the Board's report. Since the Company does not have a website, the Annual Return is not required to be uploaded.

18. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

The information on conversation of energy, technology absorption and foreign exchange earnings and outgo as stipulated under section 134 of the Companies Act, 2013 read with companies (Accounts) rules, 2014 during the year are as stated below:

(A) Conservation of energy	
(i) the steps taken or impact on conservation of energy	The activities carried out by the Company are not power intensive and the cost of the energy is insignificant.
(ii) the steps taken by the company for utilizing alternate sources of energy	
(iii) the capital investment on energy conservation equipment's	
(B) Technology absorption	
(i) the efforts made towards technology absorption	



AI4PHARMA TECH LIMITED

(ii) the benefits derived like product improvement, cost reduction, product development or import substitution	The Company has made best efforts to carry out technology absorption.
(iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)	The Company has not imported any technology during the year.
(a) the details of technology imported;	The Company has not carried out any research & development during the year under review.
(b) the year of import;	
(c) whether the technology been fully absorbed;	
(d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof; and	
(iv) the expenditure incurred on Research and Development	
(c) Foreign exchange earnings and Outgo	
The Foreign Exchange earned in terms of actual inflows during the year and outgo.	There has been no foreign exchange earnings or outgo during the year.

19. CORPORATE SOCIAL RESPONSIBILITY (CSR):

Since the Company does not fall within the criteria of turnover and/or Profit as prescribed under the provision of Section 135 of the Companies Act, 2013, the said provisions do not apply to the company.

20. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER SECTION 186 OF THE COMPANIES ACT, 2013:

The Company has not granted any loans, provided any guarantees, or made any investments during the financial year under review and hence no disclosure with respect to purpose for which such loans, guarantees and investments made are required to be made pursuant to provisions of Section 186 of the Companies Act, 2013.

21. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES:



AI4PHARMA TECH LIMITED

During the year under review, the Company has not entered into any contractual arrangements with related parties. Accordingly, the disclosure in Form AOC-2 is not applicable.

22. RISK MANAGEMENT POLICY:

The Company does not have any formal Risk Management Policy as the element of risk threatening the company's existence is very minimal. However, the Board of Directors identified from time to time the elements of risk like change in Government policies, potential change in global & domestic markets etc., and take effective steps for mitigating such risks.

23. PERFORMANCE OF SUBSIDIARY / JOINT VENTURE / ASSOCIATES COMPANIES:

No Company during the year has become or ceased to be Company's Subsidiary, Joint Ventures or Associate Companies. Hence, applicability with respect to disclosure in Form AOC-1 is not applicable for the year under review.

24. DETAILS OF COMPANY'S HOLDING/SUBSIDIARY

Silver Touch Technologies Limited bought 50.099% Stake of AI4PHARMA TECH LIMITED. Hence, the Company have a holding company Silver Touch Technologies Limited whose detail provided as follows:

Registered Office: Silver Touch House, Opp. Suryarath Complex,
Nr. White House, Panchavati Circle, Ahmedabad - 380006 - Gujarat, India
Telephone: + 91 79 40022770/1/2/3/4, **Fax:** +91-79-2656 1624;
E-mail: cs@silvertouch.com; **Website:** www.silvertouch.com

25. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE:

There are no significant and material orders passed by any Regulators or Courts or Tribunals impacting the going concern status and Company's operations in future.

26. THE DETAILS IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS:



AI4PHARMA TECH LIMITED

The Company is well equipped with adequate internal financial controls. The Company has a continuous monitoring mechanism, which enables the organization to maintain the same standards of the control systems and help them in managing defaults, if any, on timely basis because of strong reporting mechanisms followed by the Company.

27. MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR OF THE COMPANY TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT;

There are no material changes and commitments, affecting the financial position of the Company that occurred between the end of the financial year to which the financial statements relate and the date of this report.

28. DISCLOSURE OF REMUNERATION OF EMPLOYEES COVERED UNDER RULE 5(2) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014:

Pursuant to the Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014, no employee was drawing remuneration excess of the limits set out in the said rules and therefore no information is provided in this regard.

29. WHISTLE BLOWER POLICY

The Company has established a formal monitoring mechanism for Directors and employees to report concerns about unethical activity, real or suspected fraud, or violations of the Code of Conduct and Ethics. It also offers necessary safeguards against exploitation of employees who use the method and direct access to the Board in such instances. It is confirmed that no Company staff have been refused access to the Board of directors. During the fiscal year under review, the Company received no complaints using the aforementioned process.

30. AUDITORS:

Pursuant to the provisions of Section 139 and other applicable provisions of the Companies Act, 2013, read with the relevant rules made thereunder, M/s Ambalal Patel & Co. Chartered Accountants, Ahmedabad having Firm Registration No. 100305W were appointed as the Statutory Auditors of the



AI4PHARMA TECH LIMITED

Company for the first term of five consecutive years, from the conclusion of this 1st Annual General Meeting till the conclusion of the 6th Annual General Meeting to be held in the year 2030, at such remuneration as may be decided by the Board of Directors in consultation with the Statutory Auditors of the Company

31. DETAILS OF FRAUD REPORTED BY AUDITORS:

There have been no instances of fraud reported by the Auditors under Section 143(12) of the Companies Act, 2013 during the year under review.

32. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL ACT, 2013):

The company has in place an Anti-Sexual harassment policy in line with the requirement of the sexual harassment of women at workplace (prevention, Prohibition and redressed Act, 2013).

During the Financial Year under review the Company has received no complaints of sexual harassment at workplace.

Sr. no.	Particulars	No. of Complaints
1	Complaints filed during the financial year	Nil
2	Complaints disposed of during the financial year	NA
3	Complaints pending for more than 90 Days	Nil

33. MATERNITY BENEFIT PROVIDED BY THE COMPANY UNDER MATERNITY BENEFIT ACT 1961.

The Company declares that it has duly complied with the provisions of the Maternity Benefit Act, 1961. All eligible women employees have been extended the statutory benefits prescribed under the Act, including paid maternity leave, continuity of salary and service during the leave period, and post-maternity support such as nursing breaks and flexible return-to-work options, as applicable. The Company remains committed to fostering an inclusive and supportive work environment that upholds the rights and welfare of its women employees in accordance with applicable laws.



AI4PHARMA TECH LIMITED

34. APPLICATION MADE OR PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016:

During the financial period under review, no application was made under the Insolvency and Bankruptcy Code, 2016 ("IBC 2016") by your Company. No proceedings are pending under IBC 2016 against your Company.

35. COST AUDITOR

The Company does not fall within the purview of section 148 of the Companies Act, 2013 and hence, it is not required to appoint a cost auditor for the financial year 2025-2026.

36. COST RECORDS AND COST AUDIT REPORT

Maintenance of cost records and requirement of cost audit as prescribed under the provisions of Section 148(1) of the Act are not applicable for the business activities carried out by the Company.

37. INTERNAL AUDITOR

The Company is not required to appoint Internal Auditor as it does not fall within purview of section 138(1) of Companies Act, 2013 and Rule 13 of Companies (Accounts) Rules, 2014 and it is not applicable to your Company.

38. PARTICULARS OF VALUATION DONE AT THE TIME OF ONE-TIME SETTLEMENT AND VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS:

During the financial period under review, there were no instances of any one-time settlement against loans taken from Banks or Financial Institutions.

39. REVISION OF FINANCIAL STATEMENT OR BOARD'S REPORT AS PER SECTION 131:

During the year under review, there was not any application made by Company to the Tribunal for such revision of Financial Statement or Board's Report.

40. AUDIT TRAIL APPLICABILITY (AUDIT AND AUDITORS) RULES 2014 - RULE 11 OF THE COMPANIES ACT 2013.



AI4PHARMA TECH LIMITED

The Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software's.

41. OBTAINING ISIN BY NON-SMALL COMPANIES – COMPANIES (PROSPECTUS AND ALLOTMENT OF SECURITIES) SECOND AMENDMENT RULES, 2023 OF THE COMPANIES ACT 2013.

Recent amendments under the Companies (Prospectus and Allotment of Securities) Second Amendment Rules, 2023, stipulate that non-small companies must obtain an International Securities Identification Number (ISIN) for their securities to facilitate smoother trading and enhance marketability.

The company has appointed MUFG Intime India Private Limited as RTA and submitted all required documents to the RTA and also obtained ISIN.

42. ACKNOWLEDGEMENT:

Your directors place on records their sincere thanks to bankers, business associates, consultants, and various Government Authorities for their continued support extended to your companies' activities during the year under review. Your directors also acknowledge gratefully the shareholders for their support and confidence reposed on your company.

FOR AI4PHARMA TECH LIMITED,



Akshat

AKSHAT DOSHI

DIRECTOR

DIN: 10774141

PLACE: AHMEDABAD

DATE: 30-04-2026



AI4PHARMA TECH LIMITED

REGD. OFFICE

**D 510 The First BS Keshav, baug Party,
Plot, I I M, Ahmedabad, Ahmadabad City,
Gujarat, India, 380015**

AUDITORS

AMBALAL PATEL & CO LLP

CHARTERED ACCOUNTANTS

1st Floor, Saphhire Business Centre

Above Sbi Bank juna Vadaj Branch

Usmanpura

Ahmedabad-380013

**FINANCIAL YEAR
2025-26**



Ambalal Patel & Co LLP
CHARTERED ACCOUNTANTS
LLPIN : ACN - 0930

Head Office : 1st Floor,
Sapphire Business Center,
Above SBI Vadaj Branch, Usmanpura,
Ashram Road, Ahmedabad - 380 013.

Phone : 079-3533 8368 - 69 -70
E-mail : apcca1@gmail.com
Website : www.apcca.com
Branch Office : Unjha & Jamnagar

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF

M/s. AI4PHARMA TECH LIMITED

Report on the Financial Statements

Opinion

We have audited the accompanying standalone Ind AS financial statements of M/s. AI4PHARMA TECH LIMITED ("the Company"), which comprise the Balance Sheet as at 31st March 2026, the Statement of Profit & Loss including the Statement of Other Comprehensive Income, the Cash flow Statement and the Statement of Changes in Equity for the year then ended and notes to the Standalone Ind AS financial statements, including a summary of significant accounting policies and Other explanatory information

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone **Ind AS financial statements** give the information required by the Companies Act, 2013, as amended (the "Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at **March 31, 2026**, since its first year of incorporation and company is in preoperative stage so loss has arisen.

Basis for Opinion

We conducted our audit of the standalone Ind AS financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Standalone Ind AS Financial Statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone Ind AS financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone Ind AS financial statements for the financial year ended **March 31, 2026**. These matters were addressed in the context of our audit of the standalone Ind AS financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have nothing to report in this regard.

Information other than the Standalone Financial statements and Auditor's report thereon.

The Company's Board of Directors is responsible for the preparation of other information. The other information comprises the information included in the Board's report including Annexures to Board's report, but does not include the standalone financial statements and our auditor's report thereon. The Company's Annual Report is expected to be made available to us after the date of this Audit Report.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone Ind AS financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether such other information is materially inconsistent with the standalone Ind AS financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is no material misstatement of the other information, So We have nothing to report in this regard.



Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone Ind AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone Ind AS financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility

Our responsibility is to express an opinion on the standalone Ind AS financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by managements, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone Ind AS financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone Ind AS financial statements.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- 1 Identify and assess the risks of material misstatement of the standalone Ind AS financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- 2 Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- 3 Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- 4 Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- 5 Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone Ind AS financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.



Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the **Annexure A** statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As acquired by section 143(3) of the Act, we report that:
 - a. We have sought and obtain all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b. In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
 - d. In our opinion, the aforesaid standalone IndAS financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended;
 - e. On the basis of written representations received from the directors as on 31st March 2026, and taken on record by the Board of Directors, none of the directors is disqualified as on 31st March 2026, from being appointed as a director in terms of Section 164 (2) of the Act.
 - f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "**Annexure B**";
 - g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - I There is no pending litigation that may have impact on its financial statements.
 - II The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - III There is no amount to be transferred to Investors Education Protection Fund.
 - IV- (a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (b) The management has represented that, to the best of its knowledge and belief, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - (c) Based on such audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.



V The company has not paid any dividend during the year

h Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and that has operated throughout the year for all relevant transactions recorded in the software and for direct database changes throughout the year. Further, during the course of performing our procedures, we did not notice any instance of audit trail feature being tampered with in cases where the audit trail feature was enabled or audit trail not preserved by the Company as per the statutory requirements for record retention

For AMBALAL PATEL & CO LLP
Chartered Accountants
Firm Reg. No. : 100305W/W101093

CA Nilay R Bhavsar
DESIGNATED PARTNER
M.No. 137932
UDIN: 26137932AHHIOS9259

Ahmedabad
30/04/2026



ANNEXURE A TO INDEPENDENT AUDITOR'S REPORT

(Referred to paragraph 1 under the heading of "Report on Other Legal and Regulatory Requirements" of our report of even date.)

- (i) (a) The company has maintained proper records showing particulars including quantitative details and situation of intangible assets; furthermore, the company does not possess any tangible assets.
- (b) All fixed assets have not been physically verified by the management during the year but there is a regular program of verification which, in our opinion, is reasonable having regard to the size of the company and the nature of its assets. According to the information and explanations given to us no material discrepancies were noticed on such verification.
- (c) All the title deeds with respect to Immovable Properties are held in the name of the company.
- (ii) There are no Inventories with the Company, hence clause (ii) is not Applicable.
- (iii) (a) According to the information and explanation given to us, the Company has not granted any Secured, unsecured loans to companies & firms listed in the register maintained under section 189 of the Companies Act 2013.
- (iv) According to explanation given to us, In respect of loans, investments, guarantees, and security, Company has complied the provisions of section 185 and 186 of the Companies Act, 2013 .
- (v) The Company has not accepted any deposits including the amount deemed as deposit from public and hence the provision of section 73 and 76 or any other relevant provisions of the Companies Act and the rules framed there under are not applicable to Company.
- (vi) The provisions of Section 148(1) of the Companies Act, 2013 relating to maintenance of cost records is not applicable to the company.
- (vii) (a) The company has generally been regular in depositing undisputed statutory dues Income-tax, GST, custom duty, excise duty, cess, provident fund. According to the information and explanation given to us and the books and records examined by us, there are no undisputed amounts payable in respect of Income-tax, GST, custom duty, excise duty, cess, provident fund were in arrears as at 31st March 2026 for a period exceeding six months from the date they became payable.
- (b) On the basis of our examination of the documents and records, there is no disputed amount pending in respect of any statutory dues except as mentioned below:
- (viii) There are no transactions which are not recorded in the books of accounts and that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961)
- (ix) (a) The company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender during the current year.
- (b) The company is not declared as a wilful defaulter by any bank or financial institution or other lender;
- (c) The term loans raised were applied for the purpose for which the loans were obtained and there is no deviation of purpose in the current year;
- (d) Funds raised on short term basis have not been utilised for any long term purposes during the current year;
- (e) The company is not having any relation in nature of subsidiaries, associates or joint ventures and hence this sub-clause is not applicable;
- (f) The company has not raised any loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies;
- (x) (a) Company has not raised money by way of initial public offer or further public offer (including debt instruments) during the year and therefore, the provisions of clause (ix) of the order are not applicable to the company.
- (b) According to information and explanation given to us, the company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year and so, company is not required to comply section 42 of the Companies Act, 2013.



- (xi) (a) According to the information and explanation given to us and to the best of our knowledge and belief no fraud on or by the company, has been noticed or reported by the company during the year.
- (b) We have not filed any report under sub-section (12) of section 143 of the Companies Act in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, with respect to the current year;
- (c) According to the information and explanation given to us and to the best of our knowledge and belief, no whistle-blower complaints have been received during the year by the company;
- (xii) Since the company is not a Nidhi Company, relevant clause of CARO, 2020 is not applicable to the company;
- (xiii) According to information and explanation given to us, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc., as required by the Ind-AS 24.
- (xiv) (a) The provisions of Section 138 of Companies Act with respect to Internal Audit does not apply to the company, hence this clause of CARO, 2020 is not applicable to the company.
- (xv) According to information and explanation given to us, the company has not entered into any non-cash transactions with directors or persons connected with him and company has been complied the provisions of section 192 of Companies Act, 2013.
- (xvi) (a) According to information and explanation given to us, the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934;
- (b) The company has not conducted any Non-Banking Financial or Housing Finance activities during the current year;
- (c) The company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India;
- (d) The Group does not have more than one CIC as part of the Group;
- (xvii) The company has incurred cash losses in the current financial year;
- (xviii) There has been no resignation of statutory auditors during the year;
- (xix) On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.
- (xx) There is no unspent amount as required to be spent under section 135 of the Companies Act. Hence, nothing is to be reported.
- (xxi) The company is not required to prepare consolidated financial statements as per Section 129(3) of the Companies Act; Hence this clause is not applicable

For AMBALAL PATEL & CO LLP
CHARTERED ACCOUNTANTS
Firm Reg. No. : 100305W/W101093

N R Bhavsar

CA Nilay R Bhavsar
DESIGNATED PARTNER
M.No. 137932
UDIN: 26137932AHHIO9259

Ahmedabad
30/04/2026



INDEPENDENT AUDITORS' REPORT ON INTERNAL FINANCIAL CONTROL

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013

- 1 We have audited the internal financial controls over financial reporting of AI4PHARMA TECH LIMITED as at 31st March 2026 in conjunction with our audit of the Balance Sheet, Statement of Profit and Loss including the Statement of Other Comprehensive Income, Cash Flow Statement, Statement of Changes in Equity & notes forming part of financial statement.

Management's Responsibility for Internal Financial Controls


- 2 Management is responsible for establishing and maintaining internal financial controls based on the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ('the Guidance Note') issued by the Institute of Chartered Accountants of India ('the ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required by The Companies Act, 2013 ('the Act').

Auditor's Responsibility

- 3 Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing ('the Standards'), issued by the ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.
- 4 Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
- 5 We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

- 6 Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.



Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

7 In our opinion, Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

For AMBALAL PATEL & CO LLP

Chartered Accountants

Firm Reg. No. : 100305W/W101093

NR Bhavsar

CA Nilay R Bhavsar

DESIGNATED PARTNER

M.No. 137932

UDIN: 26137932AHHIOS9259



Ahmedabad

30/04/2026

AI4PHARMA TECH LIMITED
CIN-U63999GJ2024PLC155084

BALANCE SHEET AS ON 31st March 2026

(Amount in ₹ Lakhs)

Particulars		Note No.	31st March 2026	31st March 2025
I. ASSETS				
1 Non-current assets				
(a) Property, plant & Equipments		2	54.02	00.54
(b) Intangible assets		2	27.67	17.92
(c) Capital work-in-progress				
2 Current assets				
(a) Financial Assets				
(i) Cash and cash equivalents		3	08.80	02.51
(b) Other current assets		4	01.28	00.51
TOTAL			91.77	21.49
II. EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share capital		5	10.00	10.00
(b) Reserves and Surplus		6	(01.77)	(00.25)
2 LIABILITIES				
Non-current liabilities				
(a) Financial Liabilities				
(i) Borrowings		7	75.34	05.27
(b) Deferred tax liabilities (Net)			01.13	00.00
Current liabilities				
(a) Financial Liabilities				
(i) Trade payables				
(A) Total outstanding dues of MSMEs		8	00.24	
(B) Total outstanding dues of creditors other than MSMEs			00.00	03.01
(b) Other current liabilities		9	06.54	03.21
(c) Provisions		10	00.30	00.25
TOTAL			91.77	21.49
NOTES FORMING PART OF STANDALONE FINANCIAL STATEMENTS		1		

As per our report of even date
For **AMBALAL PATEL & CO LLP**
CHARTERED ACCOUNTANTS
Firm Reg. No. : 100305W/W101093

NRBhava

CA Nilay R Bhavsar
DESIGNATED PARTNER
M.No. 137932
UDIN: 26137932AHHIOS9259

Ahmedabad
30/04/2026



For and on behalf of Board of Directors

Minesh Doshi

Minesh Doshi
Director
DIN - 00306106

Akshat Doshi

Akshat Doshi
Director
DIN - 10774141

AI4PHARMA TECH LIMITED

CIN-U63999GJ2024PLC155084

STATEMENT OF PROFIT & LOSS FOR THE PERIOD ENDED ON 31th March 2026

(Amount in ₹ Lakhs)

Particulars		Note No.	31th March 2026	31st March 2025
I. Revenue from operations				
Sales of Services		11	08.87	00.00
			08.87	00.00
II. Other income			00.00	
III. Total Income (I + II)			08.87	
IV. Expenses:				
Employee benefits expense		12	03.97	00.00
Finance costs		13	00.38	00.00
Depreciation and amortization expense			02.75	00.00
Operations & Other Expenses		14	02.15	00.25
Total expenses			09.26	00.25
V Profit before tax (III- IV)			-00.39	-00.25
VI Tax expense:				
(1) Deferred tax			01.13	
			01.13	00.00
Profit (Loss) for the period from continuing operations (IX+X-XI)			-01.52	-00.25
VII Profit/(loss) from discontinuing operations				
IX Tax expense of discontinuing operations				
Profit/(loss) from Discontinuing operations (after tax) (XIII-X XVI)			00.00	00.00
XI Profit for the period (V+VI-VII)			-01.52	-00.25
XII Other Comprehensive Income				
Other Comprehensive Income (Net of Tax)			00.00	00.00
XIII Total Comprehensive Income for the period (VIII+VII)			-01.52	-00.25
IXV Earnings per equity share (Face Value ₹ 10 per share)				
(1) Basic		-	15.24	- 4.52
(2) Diluted		-	15.24	- 4.52
Notes on Accounts		1		

As per our report of even date
For AMBALAL PATEL & CO LLP
CHARTERED ACCOUNTANTS
Firm Reg. No. : 100305W/W101093

CA Nilay R Bhavsar
DESIGNATED PARTNER
M.No. 137932
UDIN: 26137932AHHIOS9259

Ahmedabad
30/04/2026

For and on behalf of Board of Directors

Minesh Doshi
Minesh Doshi
Director
DIN - 00306106

Akshat Doshi
Akshat Doshi
Director
DIN - 10774141

AI4PHARMA TECH LIMITED
U63999GJ2024PLC155084

CASH FLOW STATEMENT FOR THE PERIOD ENDED ON 31st March 2026

(Amount in ₹ Lakhs) (Amount in ₹ Lakhs)

PARTICULARS	2025-26	2024-25
A. Cash inflow/(outflow) from the operating activities		
Net profit before Tax and Prior Period Adjustments	(00.39)	(00.25)
Operating Profit before working capital changes	(00.39)	-00.25
Adjustment for (Increase)/Decrease in Working Capital :		
Other Current Asset	(00.77)	(00.51)
Other Non Current Asset	00.00	00.00
Loans & Advances	00.00	00.00
Current Liabilities & Provisions	00.61	06.47
	(00.17)	05.96
Net cash inflow/(outflow) from operating activities (A)	(00.56)	05.71
B. Cash inflow/(outflow) from investing activity		
Purchase of Assets	(63.22)	(18.46)
Net cash inflow/(outflow) from investing activity (B)	(63.22)	-18.46
C. Cash inflow/(outflow) from financing activity		
Long Term Loans Availed / (Paid)	70.07	05.27
Short Term Loans Availed / (Paid)	00.00	00.00
Other Financial Asset Availed / (Paid)		
Equity Shares Issued	00.00	10.00
Net cash inflow/(outflow) from Financing activity (C)	70.07	15.27
Net Cash changes in cash and cash equivalent (A+B+C)	06.29	02.51
Cash & Cash Equivalent at the beginning of the Period	02.51	00.00
Cash & Cash Equivalent at the end of the Period	08.80	02.51
Net Increase in cash and cash equivalent	06.29	02.51

Note :

- The Cash Flow Statement has been prepared under the Indirect Method as set out in Ind AS-7 on Cash Flow Statement notified by Companies(Accounting Standards)Rules, 2021.
- Figures In bracket represent Outflow of cash.

As Per our report of even date

For **AMBALAL PATEL & CO LLP**
CHARTERED ACCOUNTANTS
Firm Reg. No. : 100305W/W101093

NR Bhavsar

CA Nilay R Bhavsar
DESIGNATED PARTNER
M.No. 137932
UDIN: 26137932AHHIOS9259

Ahmedabad
30/04/2026



For and on behalf of Board of Directors

Minesh Doshi
Minesh Doshi
Director
DIN - 00306106

Akshat Doshi
Akshat Doshi
Director
DIN - 10774141

Notes forming Part of accounts:

Note 1 SIGNIFICANT ACCOUNTING POLICIES

i) Company Overview:

AI4Pharma Tech Limited("the company") is an innovative technology company based in Ahmedabad, Gujarat,India. Established in September,2024, the company is dedicated to leveraging artificial intelligence (AI) to address the unique challenges faced by the pharmaceutical industry. Their priority goal is to help pharmaceutical companies worldwide deliver better-quality products that are accessible and affordable for the patients everywhere.

The Company is a limited company incorporated and domiciled in India and has its registered office at D 510 The First BS Keshav Baug Party Plot IIM Ahmedabad, Gujarat 380015

ii)Basis of Preparation and presentation :

(a) Compliance with Ind-AS

It is first time adoption of Ind-AS and The financial statements of the Company have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards)Rules, 2015, as amended from time to time and presentation requirements of Division II of Schedule III to the Companies Act, 2013, (IndAS compliant Schedule III), as applicable to the Company's financial statements.. The financial statements have been prepared under the historical cost convention on accrual basis of accounting. The company is a Small Company as defined in the general instruction in respect of accounting standards notified under the Companies Act, 2013. Accordingly, the company has complied with the accounting standards as applicable to a small Company.

(b) Historical Cost Convention

The financial statements have been prepared under the historical cost convention on accrual basis of accounting.

(c) Rounding of Amounts

All amounts disclosed in financial statement and notes have been rounded off to the nearest lakhs except when otherwise indicated.

iii) Use of Estimates :

The preparation of financial statements in conformity with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards)Rules, 2015, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the results of operations during the reporting period end. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Difference between actual and estimates are recognized in the period in which the results are known/materialised.



AI4PHARMA TECH LIMITED (FY 2025-26)

iv) Property, plant and equipment & Depreciation :

Property, plant and equipment are stated at cost, net of recoverable taxes, less accumulated depreciation and impairment losses if any. Such cost included purchase price, borrowing cost and other cost directly attributable to the acquisition of the items. All other repairs and maintenance are charged to the Statement Profit and Loss during the reporting period in which they are incurred.

Depreciation is provided on fixed assets used during the year as per **Straight Line Method** on the basis of useful life of assets and residual value as specified in schedule II of the Companies Act, 2013 except on few assets, where different life has been estimated by the management where assets are for specific project. Depreciation on additions or sale/discard of asset is being provided on pro-rata basis from the date on which such asset is ready to be put to use to date of sale/discard.

The Company provides depreciation on property, plant and equipment using the Written Down Value method. The rates of depreciation are arrived at, based on useful lives estimated by the management as follows:

Block of assets	Estimated useful life (in years)
Office Buildings	60
Office equipment	3-10
Furniture and fixtures	10
Plant and Equipments	3-10
Vehicles	8

The residual value are not more than 5% of original cost of asset. The Asset residual values and useful life are reviewed and adjusted if appropriate, at the end of each reporting period.

Gains and losses on disposal are determined by comparing proceeds with carrying amount. These are included in Statement of Profit and Loss.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.



v) Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost.

Following initial recognition, intangible assets are carried at cost less accumulated amortisation and accumulated impairment losses, if any.

The useful lives of intangible assets are assessed as either finite or indefinite. There are no intangible assets assessed with indefinite useful life.

Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired.

The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the statement of profit and loss unless such expenditure forms part of carrying value of another asset. Gain or losses arising from the derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit and loss when the asset is derecognised.

Intangible assets are amortised on straightline basis as follows:

Block of assets	Estimated useful life (in years)
Computer softwares	3-6

income recognition

xvii) Revenue Recognition :

Sale of Services [Teseing Fees of Vehicle Fitness] :

The Company uses the percentage-of-completion method in accounting for its fixed-price contracts. The use of the percentage-of-completion method requires the Company to estimate the efforts or costs expended to date as a proportion of the total efforts or costs to be expended. Efforts or costsexpended have been used to measure progress towards completion as there is a direct relationship between inputand productivity. Provisions for estimated losses, if any, on uncompleted contracts are recorded in the period in which such losses become probable based on the expected contract estimates at the reporting date.

Sale of Goods:

Revenue is measured at the fair value of the consideration received or receivable. The Company recognises revenues on sale of products, net of discounts, sales incentives, rebates granted, returns, sales taxes/GST and duties when the products are delivered to customer or when delivered to a carrier for export sale, which is when title and risk and rewards of ownership pass to the customer. Export incentives are recognised as income as per the terms of the scheme in respect of the exports made and included as part of export turnover.



Dividend and interest income:

Dividend income from investments is recognised when the shareholder's right to receive payment has been established (provided that it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably). Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

vi) Cash and Cash Equivalents:

The Company considers all highly liquid financial instruments, which are readily convertible into known amounts of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase, to be cash equivalents.

Cash and cash equivalents consist of balances with banks which are unrestricted for withdrawal and usage.

viii) Cashflows

Cash Flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated. The Company considers all highly liquid investments that are readily convertible to known amounts of cash to be cash equivalents.

vii) Borrowing costs

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalisation. Other borrowing costs are expensed in the period in which they are incurred and are recognised in the statement of profit and loss.

xiv) Employee benefits

(a) Short-term obligations

Liabilities for wages and salaries, including nonmonetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognised in respect of employees' services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. These liabilities are presented as current liabilities in the balance sheet



(b) Other long-term employee benefit obligations

The liabilities for earned leave and sick leave are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. They are therefore measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. The benefits are discounted using the market yields at the end of the reporting period that have terms approximating to the terms of the related obligation.

The obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur.

(c) Post-employment obligations

The Company operates the following postemployment schemes:

- (a) defined benefit plans such as gratuity; and
- (b) defined contribution plans such as provident fund, employees state insurance taxes.

Gratuity obligations

The liability or asset recognised in the balance sheet in respect of defined benefit pension and gratuity plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by actuaries using the projected unit credit method.

The present value of the defined benefit obligation denominated in is determined by discounting the estimated future cash outflows by reference to market yields at the end of the reporting period on government bonds that have terms approximating to the terms of the related obligation. The benefits which are denominated in currency other than, the cash flows are discounted using market yields determined by reference to high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms approximating to the terms of the related obligation.

The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the statement of profit and loss.

Remeasurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognised in the period in which they occur, directly in OCI. They are included in retained earnings in the statement of changes in equity and in the balance sheet.

Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognised immediately in statement of profit and loss as past service cost.

Defined contribution plans

The Company pays provident fund and employees state insurance contributions to publicly administered provident funds as per local regulations. The Company has no further payment obligations once the contributions have been paid. The contributions are accounted for as defined contribution plans and the contributions are recognised as employee benefit expense when they are due. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in the future payments is available.



(d) Share-based payments Employee Benefits in Foreign Branch

In respect of employees in foreign branch, necessary provisions are made based on the applicable local laws. Gratuity and leave encashment / entitlement as applicable for employees in foreign branch are provided on the basis of actuarial valuation and based on estimates.

(e) Share-based payments

Share-based compensation benefits are provided to employees via the Employee Option Plan.

Employee option Plan

The fair value of options granted under the Employee Option Plan is recognised as an employee benefits expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted:

- including any market performance conditions
- excluding the impact of any service and nonmarket performance vesting conditions, and

- including the impact of any non-vesting conditions.

The total expense is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied.

At the end of each period, the entity revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. It recognises the impact of the revision to original estimates, if any, in statement of profit and loss, with a corresponding adjustment to equity.

xv) Investments :

vii) Impairment of Assets :

(i) Financial assets (other than at fair value)

The Company assesses at each date of Balancesheet whether a financial asset or a group of financial assets is impaired. Ind AS 109 requires expected credit losses to be measured through a loss allowance. The Company recognises lifetime expected losses for all contract assets and/or all trade receivables that do not constitute a financing transaction. For all other financial assets, expected credit losses are measured at an amount equal to the 12 month expected credit losses or at an amount equal to the life time expected credit losses if the credit risk or the financial asset has increased significantly since initial recognition.

(ii) Non-financial assets

Tangible and intangible assets

Property, plant and equipment and intangible assets within finite life are evaluated for recoverability whenever there is any indication that their carrying amounts may not be recoverable. If any such indication exists, the recoverable amount (i.e. higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the cash generating unit (CGU) to which the asset belongs.

If the recoverable amount of an asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (or CGU) is reduced to its recoverable amount. An impairment loss is recognised in the statement of profit and loss.



vii) Earning per Share :

(i) Basic earnings per share

Basic earnings per share is calculated by dividing:

- the profit attributable to owners of the Company
- by the weighted average number of equity shares outstanding during the financial year, adjusted for bonus elements in equity shares issued during the year and excluding treasury shares

(ii) Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account:

- the after income tax effect of interest and other financing costs associated with dilutive potential equity
- the weighted average number of additional equity shares that would have been outstanding assuming the conversion of all dilutive potential equity shares

ix) Provisions, Contingent Liabilities and Contingent Assets :

A provision is recognised when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions (excluding retirement benefits and compensated absences) are not discounted to its present value unless the effect of time value of money is material and are determined based on best estimate required to settle the obligation at the Balance sheet date. These are reviewed at each Balance sheet date and adjusted to reflect the current best estimates. Contingent liabilities and Assets are not recognised in the financial statements.

x) Income taxes

(i) Current income taxes

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date in the countries where the Group operates and generates taxable income.

Current income tax relating to items recognised outside statement of profit or loss is recognised outside statement of profit or loss (either in other comprehensive income or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate. Advance taxes and provisions for current income taxes are presented in the Balance sheet after off-setting advance tax paid and income tax provision arising in the same tax jurisdiction and where the relevant tax paying units intends to settle the asset and liability on a net basis.

(ii) Deferred income taxes

Deferred income tax is recognised using the Balance sheet approach. Deferred income tax assets and liabilities are recognised for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount, except when the deferred income tax arises from the initial recognition of an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profit or loss at the time of the transaction.



AI4PHARMA TECH LIMITED (FY 2025-26)

Deferred income tax asset are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be Utilised.

The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised.

Deferred tax assets and liabilities are measured using substantively enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to be received or settled.

Deferred tax assets and liabilities are offset when they relate to income taxes levied by the same taxation authority and the relevant entity intends to settle its current tax assets and liabilities on a net basis.

Deferred tax assets include Minimum Alternate Tax (MAT) paid in accordance with the tax laws in India, which is likely to give future economic benefits in the form of availability of set off against future economic tax liability. Accordingly, MAT is recognised as deferred tax asset in the Balance sheet when the asset can be measured reliably and it is probable that the future economic benefit associated with the asset will be realised.

The Group recognises interest levied and penalties related to income tax assessments in finance costs.





in accordance with the Ind As -36 on 'Impairment of Assets', the company has reassessed its fixed assets and is of the view that no further impairment/reversal is considered to be necessary in view of its expected realizable value.

Revaluation Of Fixed Assets:
The company has not revalued any Property, Plant and Equipment during current year.

The company does not have any Intangible Asset under development as at the end of current year.

(b) Following are the intangible assets under development, whose completion is overdue or has exceeded its cost compared to its original plan, the schedule for which is given hereby:

(Amount in Rs.)	(Amount in Lacs)

(amount in \$K)		(amount in US\$)
Intangible assets under development		
	To be completed in	
	Less than 1 year	More than 1 year
	1-2 years	More than 3 years
	NIL	
Project 1		
Project 2		

NOTE 3 CASH AND CASH EQUIVALENTS

Particulars	31/03/2026	31/03/2025
	(Amt in ₹ Lakhs)	(Amt in ₹ Lakhs)
a. Cash & Cash Equivalants		
i) Cash on hand	00.09	00.05
ii) Balance With Bank	08.71	02.47
Total	08.80	02.51

Note 4 Other Current Assets

Particulars	31/03/2026	31/03/2025
	(Amt in ₹ Lakhs)	(Amt in ₹ Lakhs)
Balance with Government	00.90	00.51
Advance to Supplier	00.18	00.00
Deposit	00.20	00.00
Total	01.28	00.51



STATEMENT OF CHANGE OF EQUITY

NOTE 5 EQUITY

Particulars	31/03/2026		31/03/2025	
	Number	(Amt in ₹ Lakhs)	Number	(Amt in ₹ Lakhs)
Authorised Equity Shares of ₹ 10 each	1,00,000	10.00	1,00,000	10.00
Issued Equity Shares of ₹ 10 each	1,00,000	10.00	1,00,000	10.00
Subscribed & Paid up Equity Shares of ₹ 10 each	1,00,000	10.00	1,00,000	10.00
Subscribed but not fully Paid up Equity Shares of ₹ 10 each, not fully paid up	-	-	-	-
Total	1,00,000	10.00	1,00,000	10.00

A. Equity Share Capital

Particulars	31/03/2026		31/03/2025	
	Number	(Amt in ₹ Lakhs)	Number	(Amt in ₹ Lakhs)
Balance at the beginning of the current reporting period	00.00	00.00	0	00.00
Changes in Equity Share Capital due to prior period errors	-	-	-	-
Restated balance at the beginning of the current reporting period	00.00	00.00	0	00.00
Changes in equity share capital during the current year	1,00,000	10.00	-	-
Balance at the end of the current reporting period	100000	10.00	0	00.00

Details of share holders holding.

Name Of Shareholders	31/03/2026		31/03/2025	
	Number of Shares	%Holding	Number of Shares	%Holding
Silver Touch Technologies Limited	50,099	50.10%	50,099	50.10%
Alkhat Minesh Doshi	225	0.23%	225	0.23%
Jignesh A. Patel	302	0.30%	302	0.30%
Palak V. Shah	72	0.07%	72	0.07%
Vipul H. Thakkar	302	0.30%	302	0.30%
Amish Pravinchandra Vyas	48,000	48.00%	48,000	48.00%
Bijal Amish Vyas	1,000	1.00%	1,000	1.00%
Total	1,00,000	100.00%	1,00,000	100.00%

Details of share holders holding more than 5% shares

Name of Shareholders	31/03/2026		31/03/2025	
	Number of Shares	% Holding	Number of Shares	% Holding
Silver Touch Technologies Limited	50,099	50%	50,099	50%
Amish Vyas Pravinchandra	48,000	48%	48,000	48%

Disclosure of Shareholding of Promoters:

Name of Shareholders	31/03/2026		31/03/2025	
	Number of Shares	% Holding	Number of Shares	% Holding
Silver Touch Technologies Limited	50,099	50%	50,099	50%
Amish Vyas Pravinchandra	48,000	48%	48,000	48%
Grand Total	98,099	98%	98,099	98%



(8) Other Equity

(i) As on 31/03/2026 (Amt in ₹ Lakhs)

Particulars	Share application money pending allotment	Equity component of compound financial instruments	Reserves and Surplus				Total
			Capital Reserve	Securities Premium	(Other Reserve) General Reserve	Retained Earnings	
Balance at the beginning of the current reporting period	-	-	-	-	-	(00.25)	(00.25)
Changes in accounting policy or prior period errors	-	-	-	-	-	-	-
Restated balance at the beginning of the current reporting period	-	-	-	-	-	(00.25)	(00.25)
Total Comprehensive Income for the current year						(01.52)	(01.52)
Dividends						-	-
Transfer to retained earnings						-	-
Any other change (to be specified)						-	-
Balance at the end of the current reporting period						(01.77)	(01.77)

(ii) As on 31/03/2025 (Amt in ₹ Lakhs)

Particulars	Share application money pending allotment	Equity component of compound financial instruments	Reserves and Surplus				Total
			Capital Reserve	Securities Premium	(Other Reserve) General Reserve	Retained Earnings	
Balance at the beginning of the current reporting period							-
Changes in accounting policy or prior period errors						-	-
Restated balance at the beginning of the current reporting period						-	-
Total Comprehensive Income for the current year						(00.25)	25,000
Dividends						-	-
Transfer to retained earnings						-	-
Any other change (Due to Ind- AS Effect)						00.00	-
Balance at the end of the current reporting period						(00.25)	25,000

As per our report of even date
For AMBALAL PATEL & CO LLP
CHARTERED ACCOUNTANTS
Firm Reg. No. : 100305W/WJ01093

Niraj
CA Nilay R Bhavsar
DESIGNATED PARTNER
M.No. 137932
UDIN: 26137932AHHIO59259
Ahmedabad
30.04.2026



For and on behalf of Board of Directors

Niraj
For and on behalf of Board of Directors

Minesh Doshi
Director
DIN - 00306106
DIN - 10774141



AI4PHARMA TECH LIMITED (FY 2025-26)

NOTE 6 RESERVE AND SURPLUS

Particulars	31/03/2026 (Amt in ₹ Lakhs)	31/03/2025 (Amt in ₹ Lakhs)
Profit & Loss A/c		
Opening balance	(00.25)	-
Add:		
Net Profit/(Net Loss) For the current year	(01.52)	(00.25)
Opening Balance Accounts(INCL LOAN TO UNDER TAKING)		
Closing Balance	(01.77)	(00.25)
Total	(01.77)	(00.25)

NOTE 7 NON CURRENT BORROWINGS

Particulars	31/03/2026 (Amt in ₹ Lakhs)	31/03/2025 (Amt in ₹ Lakhs)
Unsecured		
(a) Loans and advances from related parties		
From Directors	20.69	02.52
From Holding Company	54.65	02.75
Total	75.34	05.27

NOTE 8 TRADE PAYABLES

Particulars	31/03/2026 (Amt in ₹ Lakhs)	31/03/2025 (Amt in ₹ Lakhs)
Due to Micro, Small & medium Enterprises	00.24	00.00
Due to Others	00.00	03.01
Total	00.24	03.01

Trade Payable aging Schedule as at 31/03/2026

Particulars	31/03/2026 (Amt in ₹ Lakhs)			
	(i)MSME	(ii)Others	(iii) Disputed dues – MSME	(iv) Disputed dues - Others
Less than 1 year	00.24	0.00	0.00	0.00
Total	0.24	0.00	0.00	0.00

Particulars	31/03/2025 (Amt in ₹ Lakhs)			
	(i)MSME	(ii)Others	(iii) Disputed dues – MSME	(iv) Disputed dues - Others
Less than 1 year	00.00	03.01	0.00	0.00
Total	0.00	03.01	0.00	0.00

Check



AI4PHARMA TECH LIMITED (FY 2025-26)

NOTE 9 Other Current Liabilities

Particulars	31/03/2026	31/03/2025
	(Amt in ₹ Lakhs)	(Amt in ₹ Lakhs)
Government Dues	00.17	00.36
Security Deposit	00.38	00.00
Due to Others (Unpaid Expenses)	05.99	02.85
Total	06.54	03.21

NOTE 10 PROVISIONS

Particulars	31/03/2026	31/03/2025
	(Amt in ₹ Lakhs)	(Amt in ₹ Lakhs)
Others		
Provision for Audit Fees	00.30	00.20
Provision for Professional Fees	00.00	00.05
Provision for Expenses	00.00	00.00
Total	00.30	00.25



NOTE 11 REVENUE FROM OPERATION

Particulars	31/03/2026	31/03/2025
	(Amt in ₹ Lakhs)	(Amt in ₹ Lakhs)
Sale of software	08.87	-
Total	08.87	-

NOTE 12 EMPLOYEE BENEFITS EXPENSE

Particulars	31/03/2026	31/03/2025
	(Amt in ₹ Lakhs)	(Amt in ₹ Lakhs)
Salary Expenses	03.81	-
Bonus Expenses	00.17	-
TOTAL	03.97	00.00

NOTE 13 FINANCE COSTS

Particulars	31/03/2026	31/03/2025
	(Amt in ₹ Lakhs)	(Amt in ₹ Lakhs)
Other Interest Expenses		
Interest On Loan from Holding company	00.38	-
TOTAL	00.38	-

NOTE 14 OPERATIONS & OTHER EXPENSES

Particulars	31/03/2026	31/03/2025
	(Amt in ₹ Lakhs)	(Amt in ₹ Lakhs)
Net (Gain)/ loss on foreign currency transaction and translation	0.08	0.00
Payment to auditors	0.30	0.20
Travelling Expenses	0.92	0.00
Legal and Professional Fees	0.65	0.05
Miscellaneous Expense	0.20	0.00
TOTAL	2.15	0.25



Note 15 Capital Commitments

The estimated amount of contracts remaining to be executed on capital account and not provided for ₹ Nil. (previous year ₹ Nil).

Note 16 Contingent Liabilities

There are no contingent liability against the company:

Note 17 Pursuant to Micro, Small and Medium Enterprises Development Act, 2006, certain disclosures are required to be made relating to Micro, Small and Medium Enterprises. The company is in process of compiling relevant information from its suppliers about their coverage under the said act. Since the relevant information is not readily available, no disclosures have been made in the accounts.

Note 18 Auditor's Remuneration

	(Amt in ₹ Lakhs)	
	Current Year	Previous Year
Statutory Auditors		
- As Auditors	00.30	00.20
- Others	00.00	
Total	00.30	00.20

Note 19 Earning per share as required by Accounting Standard AS-20 as issued by the The Institute of Chartered Accountants of India.

Description	(Amt in ₹ Lakhs)	
	Current Year	Previous Year
Profit After Tax - Amount (in ₹) Lakhs	(01.52)	-00.25
Profit Attributable to Ordinary Share Holders - Amount (in ₹) Lakhs	(01.52)	(00.25)
Weighted Average No. of Equity Shares	10,000	5,534
Basic & Diluted Earning Per Share Amount in (₹)*	15.24	4.52
Nominal Value of share Amount in (₹)	10.00	10.00

* The company has no dilutive instruments during the Year ended 31/03/2026. As such Dilutive Earning Per share equals to Basic Earnings Per Share.

Note 20 In compliance with the accounting standard-22 relating to "Accounting for taxes on Income" the deferred tax liability of Current Period is debited to Profit & Loss Account.

Deferred tax working:

Particulars	(Amt in ₹ Lakhs)		
	As on 01/04/2025	Charge/ (Credit) during the Year to P & L A/c	As on 31/03/2026
Deferred tax (Assets) / Liabilities on account of depreciation	00.00	01.13	01.13
Deferred tax (Assets) / Liabilities on account of Gratuity,etc	Nil	Nil	Nil
Net Deferred tax (Assets)/ liabilities	00.00	01.13	01.13



AI4PHARMA TECH LIMITED (F.Y. 2025-26)

Note 21 Related party disclosure as required by IND AS 24 issued under the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time

List Of Related parties & Relationships

a) Holding, Subsidiaries, Fellow Subsidiaries, and Associates

1) Silvertouch Technology Ltd

b) Key Management Personnel :

c) Relatives of Key Management Personnel :

d) Enterprise over which Key Management Personnel and their relative exercise significant influence with whom transaction have taken place during the year :

SR. NO	Particulars	Holding Company	Key Management Personal	Holding Company	Key Management Personal
		2025-26	2024-25	2024-25	2024-25
	Interest Paid	0.38	0.00	0.00	0.00
A	OUTSTANDING BALANCE				
i.	Unsecured Loan				
	Silver Touch Technologies Limited	54.65		2.75	-
	Amish Pravinchandra Vyas		20.69		2.52
	TOTAL(B)	55.03	20.69	2.75	2.52

Note 22 No proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made there under.

Note 23 The company is not declared as a wilful defaulter by any bank or financial institution or other lender.

Note 24 The company is not having any relationship with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956:

Note 25 There has not been any delay in registering the charges or satisfaction with Registrar of Companies beyond the statutory period.

Note 26 The company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017

Note 27 As this is the first financial year of the Company, the requirements of Schedule III of the Companies Act, 2013 in respect of comparative figures are not applicable for this financial year.

Note 28 The company has not undergone through any Scheme of Arrangements that has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013

Note 29 There are no transactions which are not recorded in the books of accounts and that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961)

Note 30 The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

Note 31 Balances of Secured Loans, unsecured loans, Debtors, Creditors for goods, creditors for expenses, loans and advances and advance from customers are subject to confirmation.

Note 32 Figures are rounded off to Lakhs.

Signatories to Note 1 to 32

For AMBALAL PATEL & CO LLP
CHARTERED ACCOUNTANTS
Firm Reg. No. : 100305W/W101093

CA Nilay R Bhavsar
DESIGNATED PARTNER
M.No. 137932
UDIN: 26137932AHHIO59259

Ahmedabad
30/04/2026

For AI4PHARMA TECH LIMITED

(Akshat Doshi)
Director
(DIN - 10774141)

(Minesh Doshi)
Directors
(DIN - 00306106)